Information Provided By:
Fly News Breaks for July 15, 2019
BIOS
Jul 15, 2019 | 09:16 EDT
The Centers for Medicare & Medicaid Services last week included in its budget proposal funding for the new Medicare home infusion benefit for 2021, Lake Street analyst Brooks O'Neil tells investors in a research note. The Cures Act in 2016 created the benefit for all eligible seniors, and now CMS is acknowledging it exists and providing funding for it in the Medicare budget, adds the analyst. He believes this is a potentially "meaningful positive" for BioScrip as Medicare currently does not reimburse for home infusion services and the senior population will likely become a heavy user of such services. O'Neil affirms a Buy rating on the shares with a $4.50 price target.
News For BIOS From the Last 2 Days
There are no results for your query BIOS